346003

Glucagon Receptor Antagonist II

The Glucagon Receptor Antagonist II, also referenced under CAS 191034-25-0, controls the biological activity of Glucagon Receptor.

• Sinónimos: Glucagon Receptor Antagonist II, 2-(4-Pyridyl)-5-(4-chlorophenyl)-3-(5-bromo-2-propyloxyphenyl)pyrrole, L-168,049
• Fórmula empírica (notación de Hill): C₂₄H₂₀BrClN₂O
• Número de CAS: 191034-25-0
• Peso molecular: 467.79
• UNSPSC Code: 12352200
• NACRES: NA.77

Propiedades

• Quality Level: 100
• assay: ≥98% (HPLC)
• form: solid
• manufacturer/tradename: Calbiochem^®
• storage condition: OK to freeze; protect from light
• color: light beige
• solubility: DMSO: 45 mg/mL; ethanol: 45 mg/mL
• shipped in: ambient
• storage temp.: 2-8°C
• InChI: 1S/C24H20BrClN2O/c1-2-13-29-23-8-5-18(25)14-20(23)21-15-22(16-3-6-19(26)7-4-16)28-24(21)17-9-11-27-12-10-17/h3-12,14-15,28H,2,13H2,1H3
• InChI key: HHBOWXZOLYQFNY-UHFFFAOYSA-N

Descripción

General description

A cell-permeable triarylpyrrole compound that acts as a selective, non-competitive, high affinity glucagon receptor antagonist (IC₅₀ = 3.7 nM, 63 nM, and 60 nM for inhibition of labeled glucagon binding to human, murine, and canine glucagon receptor, respectively). Exhibits diminished antagonistic properties in the presence of Mg²⁺ (by ≥ 20-fold) and exhibits poor affinity for the rat, guinea pig, and rabbit glucagon receptors (IC₅₀ >1 µM). Does not inhibit binding of glucagon-like peptide-1 (GLP-1) to the homologous GLP-1 receptor even at concentrations as high as 10 µM. Does not affect ligand binding of a panel of other GPCRs and only weakly affects p38 kinase activity (IC₅₀ = 1.44 µM). Potently inhibits glucagon-induced GTP_γS binding to G_αs (IC₅₀ = 158 nM) and adenylate cyclase activation in hGLUR-CHO cells (K_b = 25 nM). Shown to be orally bioavailable in both mice and rats.

A cell-permeable triarylpyrrole compound that acts as a selective, non-competitive, high affinity glucagon receptor antagonist (IC₅₀ = 3.7 nM, 63 nM, and 60 nM for inhibition of labeled glucagon binding to human, murine, and canine glucagon receptor, respectively). Exhibits diminished antagonistic properties in the presence of Mg²⁺ (by ≥20-fold) and exhibits poor affinity for the rat, guinea pig, and rabbit glucagon receptors (IC₅₀ >1 µM). Does not inhibit binding of glucagon-like peptide-1 (GLP-1) to the homologous GLP-1 receptor even at concentrations as high as 10 µM. Does not affect ligand binding of a panel of other GPCRs and only weakly affects p38 kinase activity (IC₅₀ = 1.44 µM). Potently inhibits glucagon-induced GTP_γS binding to G_αs (IC₅₀ = 158 nM) and adenylate cyclase activation in hGLUR-CHO cells (K_b = 25 nM). Shown to be orally bioavailable in both mice and rats.

Biochem/physiol Actions

Cell permeable: yes

Primary Target
Glucagon Receptor

Product does not compete with ATP.

Reversible: no

Target IC₅₀: 3.7 nM, 63 nM, and 60 nM for inhibition of labeled glucagon binding to human, murine, and canine glucagon receptor, respectively

Packaging

Packaged under inert gas

Warning

Toxicity: Standard Handling (A)

Reconstitution

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.

Other Notes

Dallas-Yang, Q., et al. 2002. Anal. Biochem.301, 156.
Cascieri, M.A., et al. 1999. J. Biol. Chem.274, 8694.
de Laszlo, S.E., et al. 1999. Bioorg. Med. Chem. Lett.9, 641.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Información de seguridad

• Storage Class: 11 - Combustible Solids
• wgk_germany: WGK 1
• flash_point_f: Not applicable
• flash_point_c: Not applicable